https://urmc-099inhibitor.com/....covid-19-indicate-st
But, data in the durability regarding the reaction to mepolizumab during dosing periods are limited. The purpose of this study would be to investigate the effectiveness profile in clients with severe eosinophilic asthma over the 4-weekly dosing duration for various fixed mepolizumab doses. evaluation of data through the stage IIb/III DREAM research. Clients ≥12 years old with severe eosinophilic asthma were randomised (1111) to receive intravenous mepolizumab 75 mg (comparable